ES2071334T3 - Analogos de anillos fusionados de nitrogeno conteniendo heterociclos no aromaticos. - Google Patents

Analogos de anillos fusionados de nitrogeno conteniendo heterociclos no aromaticos.

Info

Publication number
ES2071334T3
ES2071334T3 ES91918058T ES91918058T ES2071334T3 ES 2071334 T3 ES2071334 T3 ES 2071334T3 ES 91918058 T ES91918058 T ES 91918058T ES 91918058 T ES91918058 T ES 91918058T ES 2071334 T3 ES2071334 T3 ES 2071334T3
Authority
ES
Spain
Prior art keywords
analogs
containing non
rings containing
aromatic hetero
fused nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91918058T
Other languages
English (en)
Spanish (es)
Inventor
Manoj C Desai
Harry R Howard
Terry J Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of ES2071334T3 publication Critical patent/ES2071334T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Eye Examination Apparatus (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Electroluminescent Light Sources (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
ES91918058T 1990-09-28 1991-08-20 Analogos de anillos fusionados de nitrogeno conteniendo heterociclos no aromaticos. Expired - Lifetime ES2071334T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59042390A 1990-09-28 1990-09-28

Publications (1)

Publication Number Publication Date
ES2071334T3 true ES2071334T3 (es) 1995-06-16

Family

ID=24362216

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91918058T Expired - Lifetime ES2071334T3 (es) 1990-09-28 1991-08-20 Analogos de anillos fusionados de nitrogeno conteniendo heterociclos no aromaticos.

Country Status (22)

Country Link
EP (1) EP0550635B1 (cg-RX-API-DMAC7.html)
JP (1) JPH0772175B2 (cg-RX-API-DMAC7.html)
CN (1) CN1060285A (cg-RX-API-DMAC7.html)
AT (1) ATE121389T1 (cg-RX-API-DMAC7.html)
AU (1) AU651145B2 (cg-RX-API-DMAC7.html)
BR (1) BR9106905A (cg-RX-API-DMAC7.html)
CA (1) CA2089736A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ387492A3 (cg-RX-API-DMAC7.html)
DE (1) DE69109125T2 (cg-RX-API-DMAC7.html)
DK (1) DK0550635T3 (cg-RX-API-DMAC7.html)
ES (1) ES2071334T3 (cg-RX-API-DMAC7.html)
FI (1) FI931370A7 (cg-RX-API-DMAC7.html)
HU (1) HUT68667A (cg-RX-API-DMAC7.html)
IE (1) IE66042B1 (cg-RX-API-DMAC7.html)
IL (1) IL99525A0 (cg-RX-API-DMAC7.html)
MX (1) MX9101274A (cg-RX-API-DMAC7.html)
NO (1) NO931151D0 (cg-RX-API-DMAC7.html)
PT (1) PT99064A (cg-RX-API-DMAC7.html)
TW (1) TW199144B (cg-RX-API-DMAC7.html)
WO (1) WO1992006079A1 (cg-RX-API-DMAC7.html)
YU (1) YU159291A (cg-RX-API-DMAC7.html)
ZA (1) ZA917744B (cg-RX-API-DMAC7.html)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716965A (en) * 1991-05-22 1998-02-10 Pfizer Inc. Substituted 3-aminoquinuclidines
AU657967B2 (en) * 1991-06-20 1995-03-30 Pfizer Inc. Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
TW202432B (cg-RX-API-DMAC7.html) * 1991-06-21 1993-03-21 Pfizer
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
EP0919245A3 (en) * 1991-09-20 2000-11-15 Glaxo Group Limited NK-1 receptor antagonist and a systemic antiinflammatory corticosteroid for the treatment of emesis
DK0613458T3 (da) * 1991-11-12 1998-02-09 Pfizer Acykliske ethylendiaminderivater som substans P receptorantagonister
EP0641328B1 (en) * 1992-05-18 2001-11-21 Pfizer Inc. Bridged aza-bicyclic derivatives as substance p antagonists
US5637699A (en) * 1992-06-29 1997-06-10 Merck & Co., Inc. Process for preparing morpholine tachykinin receptor antagonists
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
AU4396193A (en) * 1992-08-04 1994-03-03 Pfizer Inc. 3-benzylamino-2-phenyl-piperidine derivatives as substance p receptor antagonists
GB9216911D0 (en) * 1992-08-10 1992-09-23 Merck Sharp & Dohme Therapeutic agents
JP2909214B2 (ja) * 1992-08-19 1999-06-23 フアイザー・インコーポレイテツド 置換ベンジルアミノ窒素含有非芳香族複素環化合物
US5387595A (en) * 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
JP2722279B2 (ja) * 1992-12-10 1998-03-04 ファイザー・インク． アミノメチレンで置換した非芳香族複素環式化合物及びサブスタンスｐのアンタゴニストとしての使用
US5830854A (en) * 1992-12-14 1998-11-03 Merck Sharp & Dohme, Limited Method of treating cystic fibrosis using a tachykinin receptor antagonist
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
US5854262A (en) * 1993-10-07 1998-12-29 Pfizer Inc. Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
US5610165A (en) * 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
TW397825B (en) * 1994-10-14 2000-07-11 Novartis Ag Aroyl-piperidine derivatives
FR2725900B1 (fr) * 1994-10-21 1997-07-18 Sanofi Sa Utilisation d'antagonistes des recepteurs nk1 pour la preparation de medicaments a action cardioregulatrice
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
CA2251368A1 (en) * 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
US6245817B1 (en) 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
US6048900A (en) * 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
CA2251580A1 (en) * 1997-02-14 1998-08-20 Bayer Corporation Amides as npy5 receptor antagonists
CN1414953A (zh) 1999-11-03 2003-04-30 阿尔巴尼分子研究公司 芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和5－羟色胺重摄取的用途
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
US7119207B2 (en) 2000-04-10 2006-10-10 Pfizer Inc Benzoamide piperidine containing compounds and related compounds
JP4001486B2 (ja) * 2000-04-10 2007-10-31 ファイザー・プロダクツ・インク ベンゾアミドピペリジン含有化合物及び関連化合物
CA2415532C (en) 2000-07-11 2010-05-11 Albany Molecular Research, Inc. Novel 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof
AU2002211621A1 (en) * 2000-10-10 2002-04-22 Calyx Therapeutics, Inc. Tricyclic compounds and uses thereof
CN101119969B (zh) 2004-07-15 2014-04-09 阿尔巴尼分子研究公司 芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和血清素的重摄取的应用
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
DE102005027168A1 (de) * 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinoline
US7956050B2 (en) 2005-07-15 2011-06-07 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
AU2006297443B2 (en) 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0617867D0 (en) * 2006-09-11 2006-10-18 Glaxo Group Ltd Chemical compounds
CA2770486C (en) 2006-09-22 2014-07-15 Merck Sharp & Dohme Corp. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
PL2805945T3 (pl) 2007-01-10 2019-09-30 Msd Italia S.R.L. Indazole podstawione grupą amidową jako inhibitory polimerazy poli(adp-rybozy) - (parp)
CN101641099A (zh) 2007-01-24 2010-02-03 葛兰素集团有限公司 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
GB0716573D0 (en) * 2007-08-24 2007-10-03 Glaxo Group Ltd Chemical compounds
KR20100126467A (ko) 2008-03-03 2010-12-01 타이거 파마테크 티로신 키나아제 억제제
GB0804326D0 (en) * 2008-03-07 2008-04-16 Glaxo Group Ltd Novel compounds
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
JP2012526823A (ja) 2009-05-12 2012-11-01 アルバニー モレキュラー リサーチ， インコーポレイテッド アリール、ヘテロアリール、および複素環置換テトラヒドロイソキノリンならびにそれらの使用
JP5764553B2 (ja) 2009-05-12 2015-08-19 アルバニー モレキュラー リサーチ， インコーポレイテッド ７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンおよびその使用
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
EP2488028B1 (en) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
HUE044815T2 (hu) 2010-08-17 2019-11-28 Sirna Therapeutics Inc Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2699568A1 (en) 2011-04-21 2014-02-26 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
PL2925888T3 (pl) 2012-11-28 2018-03-30 Merck Sharp & Dohme Corp. Kompozycje i sposoby do stosowania w leczeniu nowotworów
RU2690663C2 (ru) 2012-12-20 2019-06-05 Мерк Шарп И Доум Корп. Замещенные имидазопиридины в качестве ингибиторов hdm2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
CN104610146A (zh) * 2015-01-23 2015-05-13 常州大学 一种3-氮杂二环[5,1,0]-7-醛及合成方法
CN105330588B (zh) * 2015-10-16 2017-09-26 辽宁中医药大学 马齿苋中生物碱Oleracone及其提取分离方法
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
AU2019317549A1 (en) 2018-08-07 2021-02-25 Msd International Gmbh PRMT5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
CN113121427B (zh) * 2021-03-19 2022-04-01 广东工业大学 一种喹啉类衍生物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3452026A (en) * 1966-03-15 1969-06-24 Bristol Myers Co Substituted 1,2,3,4-tetrahydroquinolines
FR1555552A (cg-RX-API-DMAC7.html) * 1967-07-05 1969-01-31
US4198415A (en) * 1979-01-22 1980-04-15 Eli Lilly And Company Prolactin inhibiting octahydro pyrazolo[3,4-g]quinolines
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas

Also Published As

Publication number Publication date
EP0550635A1 (en) 1993-07-14
IL99525A0 (en) 1992-08-18
DE69109125D1 (de) 1995-05-24
CN1060285A (zh) 1992-04-15
MX9101274A (es) 1992-05-04
JPH06501267A (ja) 1994-02-10
IE66042B1 (en) 1995-12-13
YU159291A (sh) 1994-01-20
BR9106905A (pt) 1993-08-17
JPH0772175B2 (ja) 1995-08-02
FI931370L (fi) 1993-03-26
EP0550635B1 (en) 1995-04-19
HU9300898D0 (en) 1993-06-28
ZA917744B (en) 1993-03-29
FI931370A0 (fi) 1993-03-26
NO931151L (no) 1993-03-26
PT99064A (pt) 1992-08-31
CA2089736A1 (en) 1992-03-29
IE913396A1 (en) 1992-04-08
NO931151D0 (no) 1993-03-26
FI931370A7 (fi) 1993-03-26
DK0550635T3 (da) 1995-09-04
WO1992006079A1 (en) 1992-04-16
HUT68667A (en) 1995-07-28
AU651145B2 (en) 1994-07-14
DE69109125T2 (de) 1995-09-28
TW199144B (cg-RX-API-DMAC7.html) 1993-02-01
CZ387492A3 (en) 1994-02-16
AU8746391A (en) 1992-04-28
ATE121389T1 (de) 1995-05-15

Similar Documents

Publication Publication Date Title
ES2071334T3 (es) Analogos de anillos fusionados de nitrogeno conteniendo heterociclos no aromaticos.
ES2127946T3 (es) Antagonistas de neurocinina diazabiciclica.
ES2164657T3 (es) Derivados aza-biciclicos puenteados como antagonistas de la sustancia p.
MX9304698A (es) Heterociclos que contienen nitrogeno substituido.
ES2092113T3 (es) Derivados fluoroalcoxibencilamino de heterociclos que contienen nitrogeno.
ES2119831T3 (es) 7-(sustituido)-9-((glicil sustituido)amido)-6-desmetil-6-desoxitetraciclinas.
ES2067466T5 (es) Dispersante.
FI864527A0 (fi) Tricyklofoereningar, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska blandning.
MX9304996A (es) Heterociclos no-aromaticos que contienen bencilamino nitrogeno substituido.
ES2162617T3 (es) Nuevas 7-(sustituido)-8-(sustituido)-9-((glicilo sustituido)amido)-6-desmetil-6-desoxitetraciclinas.
ES2066991T3 (es) Agentes hipoglucemiantes de oxazolidinadiona.
ES2132373T3 (es) Benzocicloheptenos, benzoxepinas y benzotiepinas.
AR247389A1 (es) Derivados de 2,4-diamino-5-ciano-pirimidinas, excluidos sus usos terapeuticos, procedimiento para su preparacion, intermediarios y composiciones que las contienen como antiparasitarios
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
AR245713A1 (es) Derivados de acido 1-heterociclil-1h-imidazol-5-carboxilico, procedimiento para su produccion y composiciones herbicidas que los comprenden.
ES2110260T3 (es) Androstenonas.
ES8707243A1 (es) Un procedimiento para preparar derivados de tienopiridona
AR246962A1 (es) Procedimiento para preparar derivados alquilamino-alquilenicos de ciertos 2h-1-benzopiranos.
ES2052598T3 (es) Derivados de hetaril-oxi-beta-carbolinas, su preparacion y utilizacion como medicamentos.
BR9708418A (pt) Amino-e trifenil-s-triazinas hodroxissubstituídas como estabilizadores
FR2400008A1 (fr) Agents anti-hypertensifs
AR004664A1 (es) Compuestos de dihalopropeno, insecticidas que los contienen como ingredientes activos, y compuestos intermedios para su produccion
DOP2002000443A (es) Proceso para produccion de quinazolinas
ES2059595T3 (es) Beta-carbonil-carboxiamidas de 1,3-tiazolidinas.
MX9303966A (es) Derivados de benzotiazepina y benzoxazepina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 550635

Country of ref document: ES